Objective To explore the predictive value of systemic immune inflammation index on the prognosis of advanced non-small cell lung cancer patients.Methods From January 2019 to June 2022,143 patients with advanced non-small cell lung cancer admitted to our hospital were retrospectively collected.Patients were followed up for 1 year to observe whether they had experienced tumor specific death or not.The patients were divided into a death group(n=67)and a control group(n=76).The differences in systemic immune inflammation index and other clinical features be-tween the two groups were compared,and the risk factors for death in advanced non-small cell lung cancer were ana-lyzed.The predictive value of systemic immune inflammation index for tumor specific death was also analyzed.Results Compared with the control group,the maximum diameter of the primary tumor in the death group increased(5.66±2.53 cm vs 4.79±1.91 cm,P=0.020);the level of SII significantly increased(522.44±242.98 vs 277.84±100.67,P＜0.001);the proportion of patients with TNM stage Ⅳ increased(76.12％vs 55.26％,P=0.011);and the propor-tion of patients with pleural effusion increased(92.54％vs 68.42％,P＜0.001).Both SII and the maximum diameter of the primary tumor were valuable in predicting the tumor specific death in advanced non-small cell lung cancer pa-tients,with areas under the curve of 0.849(95％confidence interval:0.749～0.909,P＜0.001)and 0.598(95％confi-dence interval:0.503～0.693,P=0.044).The maximum diameter of the primary tumor,pleural effusion and SII were independent influencing factors for tumor specific mortality in advanced non-small cell lung cancer patients(P＜0.05).Conclusion The elevated systemic inflammatory index in advanced non-small cell lung cancer patients is associated with tumor specific mortality and can serve as a predictive indicator for prognosis.
systemic immune inflammation indexnon small cell lung cancerTumor specific deathpredict
维普
万方数据
